Amicus gets French approval for BioMarin merger

Amicus Therapeutics, Inc. reports that the French Ministry of Economics and Finance granted clearance on April 23, 2026 for its planned merger with BioMarin Pharmaceutical under French foreign direct investment screening rules.

Rhea-AI Filing Summary

Amicus Therapeutics, Inc. reports that the French Ministry of Economics and Finance granted clearance on April 23, 2026 for its planned merger with BioMarin Pharmaceutical under French foreign direct investment screening rules. This clearance satisfies the final outstanding regulatory condition to the merger, aside from items customarily completed at closing.

The merger, under which Amicus will become a wholly owned subsidiary of BioMarin, is now expected to close on April 27, 2026, subject to those remaining closing conditions. The company also reiterates that statements about the expected timing of completion are forward-looking and subject to various risks and uncertainties.

Positive

• Final regulatory clearance obtained: The French Ministry of Economics and Finance granted foreign direct investment clearance on April 23, 2026, described as satisfying the last remaining merger condition other than standard closing requirements, paving the way for completion of the BioMarin acquisition.
• Expected near-term closing: With regulatory conditions met, the merger in which Amicus will become a wholly owned subsidiary of BioMarin is now expected to close on April 27, 2026, signaling an imminent change of control for shareholders.

Negative

• None.

Insights

M&A and biotech regulatory analyst

French approval removes the last major regulatory hurdle before BioMarin’s acquisition of Amicus, with closing expected on April 27, 2026.

The clearance from the French Ministry of Economics and Finance under foreign direct investment screening rules is described as the final condition to the merger other than standard closing items. This indicates that key regulatory reviews have now been completed, allowing the transaction to move toward completion.

The filing states that Amicus will survive the merger as a wholly owned subsidiary of BioMarin, confirming a full change of control structure. While the merger is expected to close on April 27, 2026, the forward-looking statement language highlights remaining uncertainties tied to closing mechanics, potential legal proceedings and broader risk factors previously disclosed by both companies.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

French FDI clearance date: April 23, 2026 Merger agreement date: December 19, 2025 Expected merger closing date: April 27, 2026

3 metrics

French FDI clearance date April 23, 2026 Clearance granted for the Amicus–BioMarin merger by the French Ministry of Economics and Finance

Merger agreement date December 19, 2025 Agreement and Plan of Merger signed between Amicus, BioMarin and Merger Sub

Expected merger closing date April 27, 2026 Expected closing date for Amicus to become a wholly owned subsidiary of BioMarin

Key Terms

Agreement and Plan of Merger, foreign direct investment screening, forward-looking statements, wholly owned subsidiary

4 terms

Agreement and Plan of Merger financial

"Amicus entered into an Agreement and Plan of Merger with BioMarin and Lynx Merger Sub 1, Inc."

An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.

foreign direct investment screening regulatory

"clearance for the Merger under the French foreign direct investment screening procedures"

forward-looking statements regulatory

"Forward Looking Statements Disclaimer This ... contains forward-looking statements about, among other things, expectations for the date of closing"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

wholly owned subsidiary financial

"with Amicus surviving the Merger as a wholly owned subsidiary of BioMarin"

A wholly owned subsidiary is a company whose entire ownership is held by another company (the parent), so the parent controls decisions, operations, and finances. Think of it as a fully controlled branch that runs as its own legal entity but whose results flow straight into the parent’s financial statements; investors watch these structures because they affect consolidated revenue, risk exposure, and how profits, liabilities, and cash flow are allocated across the corporate group.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amicus Therapeutics (FOLD) announce about its merger with BioMarin?

Amicus Therapeutics announced that the French Ministry of Economics and Finance granted clearance for its merger with BioMarin under foreign direct investment rules. This approval satisfies the final merger condition other than standard closing items, allowing the deal to move toward completion.

Why is the French FDI clearance important for Amicus Therapeutics’ merger?

The French foreign direct investment clearance is described as the final condition required under the merger agreement, aside from closing mechanics. Receiving this approval removes a key regulatory hurdle and allows Amicus and BioMarin to proceed toward completing their agreed merger transaction.

When is the Amicus Therapeutics and BioMarin merger expected to close?

The merger between Amicus Therapeutics and BioMarin is expected to close on April 27, 2026. This timing remains subject to satisfaction of conditions that are, by their nature, completed at closing, as highlighted in the companies’ forward-looking statements language.

What will happen to Amicus Therapeutics after the BioMarin merger closes?

After closing, Amicus Therapeutics will survive the transaction as a wholly owned subsidiary of BioMarin. This means BioMarin will own all of Amicus, and Amicus will operate under BioMarin’s corporate structure rather than as an independent public company.

What risks and uncertainties still affect the Amicus–BioMarin merger?

The companies note risks related to consummating the merger in the anticipated timeframe, the overall regulatory and legal environment, and other factors in their Form 10-K risk factors and proxy materials. These risks could cause actual outcomes to differ from current expectations about timing and completion.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/23/2026 - 04:09 PM Learn about SEC filing dates

false2026-04-14000117887900011788792026-04-142026-04-14false000117887900011788792026-04-232026-04-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 23, 2026

AMICUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-33497	71-0869350
(State of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

47 Hulfish Street, Princeton, New Jersey		08542
(Address of principal executive offices and zip code)		(Zip Code)

Registrant’s telephone number, including area code: (609) 662-2000

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.01 per share		FOLD		NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

As previously disclosed, on December 19, 2025, Amicus Therapeutics, Inc. ("Amicus") entered into an Agreement and Plan of Merger (the "Merger Agreement") with BioMarin Pharmaceutical Inc. ("BioMarin") and Lynx Merger Sub 1, Inc., a wholly owned subsidiary of BioMarin ("Merger Sub"), providing for the merger of Merger Sub with and into Amicus (the "Merger"), with Amicus surviving the Merger as a wholly owned subsidiary of BioMarin.

On April 23, 2026, the Ministry of Economics and Finance in France granted clearance for the Merger under the French foreign direct investment screening procedures (the "French FDI Clearance"). Under the Merger Agreement, receipt of the French FDI Clearance satisfies the final condition to the Merger other than conditions that by their nature are to be satisfied at the closing of the Merger. The Merger is expected to close on April 27, 2026.

Forward Looking Statements Disclaimer

This Current Report on Form 8-K contains forward-looking statements about, among other things, expectations for the date of closing of the Merger and other statements that are not historical facts. Actual results could differ materially from those anticipated in these forward-looking statements. Except as required by law, each of BioMarin and Amicus assumes no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent each of BioMarin's and Amicus' current expectations or beliefs concerning various future events that are subject to significant risks and uncertainties, may contain words such as "may," "will," "would," "could," "expect," "anticipate," "intend," "plan," "believe," "estimate," "project," "seek," "should," "strategy," "future," "opportunity," "potential" or other similar words and expressions indicating future results.

These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including, without limitation, with respect to: consummating the Merger in the anticipated time frame, if at all; the time-consuming and uncertain regulatory approval process; any legal proceedings related to the Merger; and other risks and uncertainties affecting BioMarin and Amicus, including those risk factors detailed in BioMarin's and Amicus' filings with the Securities and Exchange Commission, including, without limitation, the risk factors contained under the caption "Risk Factors" in BioMarin's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and Amicus' Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as such risk factors may be updated by any subsequent reports, as well as the Proxy Statement on Schedule 14A filed by Amicus in connection with the Merger (as amended and/or supplemented). Stockholders of BioMarin and Amicus are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin and Amicus are under no obligation, and expressly disclaim any obligation, to update (publicly or otherwise) or alter any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Amicus Therapeutics, Inc.
Dated: April 23, 2026	By:	/s/ Ellen S. Rosenberg
		Name: Ellen S. Rosenberg
		Title: Chief Legal Officer and Corporate Secretary

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 21.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 15.7 KB